Long-term clinical follow-up of the resorbable magnesium scaffolds in acute coronary syndrome patients

Abstract

Background: Research on the resorbable magnesium scaffolds (RMSs) has shown their safety and effectiveness in stable clinical conditions. It seems that this new therapeutic option could be promising for selected acute coronary syndrome (ACS) patients. Aims: Our analysis aims to analyze the long-term performance of RMSs among ACS patients. Methods: The study population consisted of consecutive ACS patients treated with the implantation of at least one RMS. The Magmaris ACS Registry was designed as a single-arm observational registry in the 'real-world' treatment practice setting. Results: The study population consisted of 193 patients, predominantly male (78%), at a mean (SD) age of 64 (9) years and with typical risk factors of ACS. Unstable angina (UA) was the indication for revascularization in 32.1%, non-ST-segment elevation myocardial infarction (NSTEMI) in 65.8% and ST-segment elevation myocardial infarction (STEMI) only in 2.1%. During the mean 24 months of follow- up, ten cases (5.2%) of target lesion failure (TLF) were diagnosed, of which five cases (2.6%) were clinically driven target lesion failure (CD-TLR), four cases (2.1%) were asymptomatic scaffold restenosis and one case (0.5%) was target vessel myocardial infarction (TV-MI). No cardiac deaths and 2 non-cardiac deaths (2.2%, both strokes) were observed. No cases of scaffold thrombosis were observed during the median 24-month follow-up. Conclusions: The use of the RMSs in selected ACS patients is associated with procedural safety and promises early and long-term clinical efficacy and safety outcomes. Appropriate lesion selection is the key to the long-term success of bioresorbable technology in this patient population.